Dr. Jones Presents Research Results at the 2015 American Society of Pharmacology & Experimental Therapeutics Meeting in Boston on March 31st

Dr. Jones had the opportunity to present “Death Effects of Reveromycin A in Normal and Diseased Synoviocytes,” a follow up study from work published by his lab earlier this year in the Journal of Cellular Biochemistry. The results presented in Boston suggest that the potential osteoporosis agent, reveromycin A, may have undesirable programmed cell death effects in normal synoviocytes of the joint under acidic conditions at a concentration of 10 micromolar. However at lower, potentially therapeutic doses, programmed cell death effects do not appear to occur. Reveromycin A effects were also characterized in fibroblast-like synoviocytes (FLS), a cell type that proliferates in joint disease, contributing to joint pathology. In this same study reveromycin A-treated FLS from rheumatoid arthritis patients were resistant to programmed cell death at an acidic pH. The work generated a published abstract in the FASEB Journal and showcased work of graduating senior, Haley Svrcina. Other current and graduated student authors on the project were Austin Greer, Ellen Steinke, Kelsey Davitt, Emily Sloane, Nathan Granger, and Calli Williams.